NEW YORK, March 16, 2017 -- Mercer International Inc. (Nasdaq:MERC) (TSX:MERC.U) (the "Company") today announced that it intends to offer for sale (the "Offering") $25.0 million in aggregate principal amount of its senior notes due 2024 (the "Additional Notes"). The Additional Notes will be issued as additional notes under the indenture dated February 3, 2017, pursuant to which the Company previously issued $225.0 million aggregate principal of 6.500% senior notes due 2024 (the "Existing Notes"). The Additional Notes will have the same CUSIP number as, and are expected to be fully fungible with, rank equally with and form a single series with, the Existing Notes.
The net proceeds of the Offering, along with cash on hand, will be used to finance the Company's acquisition of substantially all of the assets comprising a sawmill and bio-mass power plant located near Friesau, Germany and for general working capital purposes.
The Additional Notes will be offered and sold to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. The Additional Notes have not been registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Additional Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
Mercer International Inc. is a global pulp manufacturing company.
The preceding contains "forward looking statements" within the meaning of federal securities laws and is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding preliminary estimated financial results, the Company's intentions regarding the consummation of the Offering, the intended use of proceeds and the Company's proposed acquisition. "Forward looking statements" involve unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. These statements are based on the Company's management's estimates and assumptions with respect to future events, which include uncertainty as to its ability to consummate the Offering or complete its proposed acquisition, which estimates are believed to be reasonable, though inherently uncertain and difficult to predict. A discussion of factors that could cause actual results to vary is included in the Company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission.
APPROVED BY: Jimmy S.H. Lee Executive Chairman (604) 684-1099 David M. Gandossi, FCPA, FCA Chief Executive Officer (604) 684-1099


AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 



